$199.00
Tirzepatide
Next-generation dual GLP-1/GIP receptor agonist offering superior weight loss and metabolic benefits compared to semaglutide with enhanced glycemic control.
- Strong weight loss effects (dual GIP/GLP-1 agonist)
- Improves glycemic control (HbA1c reduction)
- Reduces appetite and cravings
- API per Vial: 20 mg
- Dose: 2.5mg-15mg weekly
- Frequency: Once weekly
- Route: SQ
47 in stock
Description
Dual GLP-1 and GLP Receptor Agonist
Tirzepatide is a synthetic peptide that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It has been studied for its ability to support healthy blood sugar regulation, improve insulin sensitivity, and promote clinically meaningful weight reduction.
Key Benefits
- Supports balanced glucose metabolism
- Enhances insulin sensitivity
- Reduces appetite and caloric intake
- Slows gastric emptying to promote satiety
- Supports significant body weight reductions
Scientific Highlights
- Dual GIP/GLP-1 receptor activation leads to synergistic metabolic effects
- Demonstrated robust improvements in HbA1c and fasting glucose levels in clinical studies
- Associated with substantial and sustained reductions in body weight
Contents: 20 mg active ingredient per vial
This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Overview
Tirzepatide Dual GIP/GLP-1 Agonist
Category: Weight Management & Metabolism
How It Works
Dual GIP/GLP-1 receptor agonist for superior metabolic control
Benefits
- Strong weight loss effects (dual GIP/GLP-1 agonist)
- Improves glycemic control (HbA1c reduction)
- Reduces appetite and cravings
- Improves insulin sensitivity
- Provides cardiometabolic protection
Best For
- Weight loss
- Metabolic syndrome
- Type 2 diabetes
- Body composition
Recommended Protocol
| API per Vial | 20 mg |
|---|---|
| Dosage | 2.5mg-15mg weekly |
| Frequency | Once weekly |
| Administration | SQ |
| Cycle Length | Continuous (chronic therapy) |
| Break Period | No defined breaks |
| Half-Life | ~5 days |
Safety Information
Experience Level: Intermediate
Medical Supervision: Not Required
Contraindications
- Family history of MTC
- Family history of MEN2
- Personal history of pancreatitis
Recommended Monitoring
- Monitor weight loss
- Track metabolic markers
- Watch for GI effects
Regulatory Status: FDA-approved for Type 2 diabetes (Mounjaro) and weight management (Zepbound)
Additional Notes
Dual GIP/GLP-1 agonist. More potent than semaglutide for weight loss. CONTRAINDICATION: Family history of MTC/MEN2.
